Off-label uses of TNF-a inhibitors and IL-12/23 inhibitors in dermatology.
Dermatol Online J
; 27(11)2021 Nov 15.
Article
em En
| MEDLINE
| ID: mdl-35130397
ABSTRACT
TNF-a inhibitors, which include adalimumab, infliximab, etanercept, certolizumab, and golimumab, and IL-12/23 inhibitor, ustekinumab, have been widely used as a U.S. Food and Drug Administration (FDA) approved for the treatment of psoriasis. Outside of psoriasis, high levels of TNF-a had also been found in several skin diseases including hidradenitis suppurativa. IL-12 and IL-23 play important role in the pathogenesis of SLE, alopecia areata, and vitiligo. This paper reviews the off-label uses of TNF-a inhibitors and IL-12/23 inhibitors in skin disorders.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Dermatologia
/
Uso Off-Label
/
Inibidores do Fator de Necrose Tumoral
/
Inibidores de Interleucina
Limite:
Humans
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article